Abstract
110 patients with far advanced head and neck squamous or testicular carcinoma were treated with bleomycin given by intravenous (i.v.) or intramuscular (i.m.) injection according to a randomized assignment. While responses were observed more frequently in patients treated by the intramuscular route, no superiority can be attributed clearly to intramuscular therapy. Responses were seen in 6.2% of head and neck squamous carcinoma patients (5/81; i.m. 3/38, 8%; i.v. 2/41, 5%) while 14% of testicular tumors responded (4/29; i.m. 4/13, 29%; i.v. 0/16, 0%). Toxicity was, in general, manageable.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Age Factors
-
Aged
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Bleomycin / therapeutic use*
-
Carcinoma / drug therapy*
-
Carcinoma, Squamous Cell / drug therapy*
-
Female
-
Fever / chemically induced
-
Gastrointestinal Diseases / chemically induced
-
Head and Neck Neoplasms / drug therapy*
-
Humans
-
Lung / drug effects
-
Lung Neoplasms / drug therapy
-
Lymphatic Metastasis / prevention & control
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local / prevention & control
-
Skin Diseases / chemically induced
-
Testicular Neoplasms / drug therapy*